11. TERMINATION OF STUDY 
Your participation in this research study may be ended without your consent 
for the following reasons 
1. If your tumor does not respond or gets substantially larger during 
treatment . 
2. If the doctors treating you see side effects that they consider 
dangerous . 
3. If you refuse to have treatment as recommended by your doctor or if 
you refuse to have the tests needed to determine whether the treatment is safe 
and effective. 
4. Pregnancy or failure to practice effective contraception. 
12. PRIOR REVIEW. 
This research study was reviewed by the Institutional Review Board of the 
University of Illinois at Chicago (UIC), the University's Biosafety Committee, 
and the NIH Recombinant DNA Advisory Committee of the National Institutes of 
Health. The UIC Board is legally responsible for making sure that research 
with patients is appropriate and that the patient's rights and welfare are 
protected. 
The physician in charge of this research study is Tapas K. Das Gupta, M.D., 
Ph.D., telephone number (312) 996-6666. If you need more information about 
the study before you decide to join, or at any other time, you can contact 
him. In the event you decide to participate, Dr. Das Gupta or one of his 
collaborating physicians (Dr. Edward Cohen, (312) 996-9479 or Dr. Jon Richards 
(3120 996-6666) should be called whenever there are side-effects from the 
research study. The nurse oncologist who will assist you in all non 
physician-related questions and will coordinate your therapy program is Mary 
Trippon, R.N., telephone number (312) 996-6913. 
Recombinant DNA Research, Volume 18 
